Exogen Medicare Coverage Reconsideration Attracts Physician Support
This article was originally published in The Gray Sheet
Executive Summary
Unrestricted national coverage for Smith & Nephew's Exogen ultrasonic bone growth stimulator is warranted due to potential cost savings, high patient compatibility and shorter treatment times compared to surgery, practitioners and patients tell CMS